公开(公告)号：US20210238182A1

公开(公告)日：2021-08-05

申请号：US17079951

申请日：2020-10-26

Applicant: H. Lundbeck A/S

Inventor： Jan Kehler ,  Lars Kyhn Rasmussen ,  Morten Langgård ,  Mikkel Jessing ,  Karsten Juhl ,  Paulo Jorge Vieira Vital

IPC: C07D487/04 ,  C07D519/00

Abstract: The present invention provides imidazopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

公开(公告)号：US20210023056A1

公开(公告)日：2021-01-28

申请号：US17060742

申请日：2020-10-01

Applicant: H. Lundbeck A/S

Inventor： Jan Kehler ,  Karsten Juhl ,  Mauro Marigo ,  Paulo Jorge Vieira Vital ,  Mikkel Jessing ,  Morten Langgård ,  Lars Kyhn Rasmussen ,  Carl Martin Sebastian Clementson

IPC: A61K31/4162 ,  A61K31/4745 ,  C07D413/04 ,  C07D471/04

Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

公开(公告)号：US10538525B2

公开(公告)日：2020-01-21

申请号：US16051612

申请日：2018-08-01

Applicant: H. Lundbeck A/S

Inventor： Karsten Juhl ,  Mikkel Jessing ,  Morten Langgård ,  Paulo Jorge Vieira Vital ,  Mauro Marigo ,  Jan Kehler ,  Lars Kyhn Rasmussen

IPC: C07D487/04 ,  C07D471/04 ,  A61K31/437 ,  A61K31/519

Abstract: The present invention provides 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

公开(公告)号：US20190282571A1

公开(公告)日：2019-09-19

申请号：US16345136

申请日：2017-10-26

Applicant: H. Lundbeck A/S

Inventor： Jan Kehler ,  Lars Kyhn Rasumssen ,  Morten Langgård ,  Mikkel Jessing ,  Paulo Jorge Vieira Vital ,  Karsten Juhl

IPC: A61K31/4985 ,  A61K31/553 ,  A61K31/5377 ,  A61K45/06 ,  A61P25/22 ,  A61P25/24 ,  A61P25/18 ,  A61P25/28

Abstract: The present invention provides combination treatments comprising administration of compounds that are PDE1 enzyme inhibitors and other compounds useful in the treatment of psychiatric and/or cognitive disorders such as for example Attention Deficit Hyperactivity Disorder (ADHD), depression, anxiety, narcolepsy, schizophrenia, cognitive impairment or cognitive impairment associated with schizophrenia (CIAS). Separate aspects of the invention are directed to the combined use of said compounds for the treatment of psychiatric and/or cognitive disorders. The present invention also provides phannaceutical compositions comprising said PDE1 enzyme inhibitors together with other compounds useful in the treatment of psychiatric and/or cognitive disorders.

公开(公告)号：US10034861B2

公开(公告)日：2018-07-31

申请号：US15637920

申请日：2017-06-29

Applicant: H. Lundbeck A/S

Inventor： Jan Kehler ,  Karsten Juhl ,  Mauro Marigo ,  Paulo Jorge Vieira Vital ,  Mikkel Jessing ,  Morten Langgård ,  Lars Kyhn Rasmussen ,  Carl Martin Sebastian Clementson

IPC: C07D401/14 ,  A61K31/437 ,  A61K31/4162 ,  A61K31/4745 ,  C07D413/04 ,  C07D471/04 ,  C07D305/06 ,  C07D401/04

Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

公开(公告)号：US09649308B2

公开(公告)日：2017-05-16

申请号：US14744103

申请日：2015-06-19

Applicant: H. Lundbeck A/S

Inventor： John Paul Kilburn ,  Lars Kyhn Rasmussen ,  Mikkel Jessing ,  Eman Mohamed Eldemenky ,  Bin Chen ,  Yu Jiang ,  Allen T. Hopper

IPC: A61K31/505 ,  C07C233/66 ,  C07C233/73 ,  C07C233/75 ,  C07C233/78 ,  C07D211/26 ,  C07D213/40 ,  C07D213/61 ,  C07D231/12 ,  C07D233/64 ,  C07D237/08 ,  C07D239/26 ,  C07D241/12 ,  C07D309/04 ,  C07D401/06 ,  C07D403/06 ,  C07D405/04 ,  C07D405/06 ,  C07D403/04

CPC classification number: A61K31/505 ,  C07C233/66 ,  C07C233/73 ,  C07C233/75 ,  C07C233/78 ,  C07C2601/08 ,  C07D211/26 ,  C07D213/40 ,  C07D213/61 ,  C07D231/12 ,  C07D233/64 ,  C07D237/08 ,  C07D239/26 ,  C07D241/12 ,  C07D309/04 ,  C07D401/06 ,  C07D403/04 ,  C07D403/06 ,  C07D405/04 ,  C07D405/06

Abstract: The present invention is directed to benzamide-containing compounds of formula I or pharmaceutically acceptable salts thereof which inhibit the P2X7 receptor, and their use in the treatment of pain.

公开(公告)号：US20170128460A1

公开(公告)日：2017-05-11

申请号：US15415073

申请日：2017-01-25

Applicant: H. Lundbeck A/S

Inventor： John Paul Kilburn ,  Lars Kyhn Rasmussen ,  Mikkel Jessing ,  Eman Mohamed Eldemenky ,  Bin Chen ,  Yu Jiang

IPC: A61K31/553 ,  A61K31/5375 ,  A61K31/4453 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/40 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/445

CPC classification number: A61K31/553 ,  A61K31/40 ,  A61K31/445 ,  A61K31/4453 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/5375 ,  A61K31/5377 ,  A61K31/625 ,  C07D209/52 ,  C07D211/38 ,  C07D213/40 ,  C07D239/26 ,  C07D267/10 ,  C07D295/13 ,  C07D401/06 ,  C07D403/06 ,  C07D413/06

Abstract: The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor.

公开(公告)号：US20230416272A1

公开(公告)日：2023-12-28

申请号：US18331289

申请日：2023-06-08

Applicant: H. Lundbeck A/S ,  Vernalis (R&D) Limited

Inventor： Thomas Jensen ,  Mikkel Jessing ,  Wanwan Yu ,  David Rodriguez Diaz ,  Jacob Nielsen ,  Christopher Richard Jones ,  Thomas Andersen ,  Mikkel Fog Jacobsen

IPC: C07D498/22

CPC classification number: C07D498/22 ,  C07B2200/05

Abstract: The present invention is directed to compounds of formula I




The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Parkinson's disease.

公开(公告)号：US11851425B2

公开(公告)日：2023-12-26

申请号：US16772612

申请日：2018-12-12

Applicant: H. Lundbeck A/S

Inventor： Jan Kehler ,  Karsten Juhl ,  Mauro Marigo ,  Paulo Jorge Vieira Vital ,  Mikkel Jessing ,  Morten Langgård ,  Lars Kyhn Rasmussen ,  Carl Martin Sebastian Clementson

IPC: C07D471/04 ,  C07D413/14 ,  C07D401/14 ,  C07D407/14 ,  C07D409/14

CPC classification number: C07D413/14 ,  C07D401/14 ,  C07D407/14 ,  C07D409/14

Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound useful in the treatment of a neurodegenerative disorder and their combined use as a medicament, in particular for the treatment of neurodegenerative and/or cognitive disorders.

公开(公告)号：US11780851B2

公开(公告)日：2023-10-10

申请号：US18049802

申请日：2022-10-26

Applicant: H. Lundbeck A/S ,  Vernalis (R&D) Limited

Inventor： Thomas Jensen ,  Mikkel Jessing ,  Wanwan Yu ,  David Rodriguez Diaz ,  Jacob Nielsen ,  Christopher Richard Jones ,  Thomas Andersen ,  Mikkel Fog Jacobsen

IPC: C07D498/22

CPC classification number: C07D498/22 ,  C07B2200/05

Abstract: The present invention is directed to compounds of formula I




The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Parkinson's disease.